ZERO Prostate Cancer’s Post

How my entrepreneurial mindset sparked the launch of a pickleball paddle and apparel company in the wake of a cancer diagnosis. Watch this episode of The Primal Mindset to learn more. https://lnkd.in/gp5RQwS4

As Professor David Thomas said in a symposium called ‘Shaping the future of personalized healthcare for cancer patients’ at the recent ESMO - European Society for Medical Oncology conference, there’s a widening gap between the potential of science to improve health and affordability. At the WCLC and ESMO conferences I was fortunate to attend in the last two months, there were a number of practice-changing readouts of novel treatment regimens across cancer types. For example, take the combination of the ADC EV-302 and pembrolizumab in 1L advanced or metastatic bladder cancer, which almost doubled the median overall survival of chemotherapy (31.5 vs 16.1 months), the standard of care to date - receiving a standing ovation. The question that immediately arises is: will patients with bladder cancer across different healthcare systems be able to access this novel combination? If so, when? (of course, I’m only referring to high-income countries). It’ll be interesting to watch how reimbursement plays out, especially in cost-effectiveness-driven systems, such as the UK, Australia, South Korea or Taiwan. As the two agents are marketed by different pharmaceutical companies, and presumably MSD won’t lower the price of their blockbuster pembrolizumab to make this novel combo affordable, which would impact all their other indications, will Astellas/Seagen take the hit? Are risk-sharing agreements (proper ones, not straight expenditure caps) the solution? Back to the initial statement, the current access paradigm in oncology needs to change to keep up with the pace of innovation.

Breast cancer is a disease in which abnormal breast cells grow out of control and form tumors. If left unchecked, tumors can spread throughout the body and become fatal. Breast cancer cells start within the milk ducts and/or lobules of the breast that produce milk. The earliest form (in situ) is not life-threatening and can be detected in the early stages. Cancer cells can spread into nearby breast tissue (invasion). This creates tumors that cause lumps or thickening. Invasive cancers can spread to nearby lymph nodes or other organs (metastasize). Metastases can be life-threatening and fatal. Treatment is based on the person, the type of cancer and how it has spread. Treatment combines surgery, radiation therapy and drugs. In 2022, there were 2.3 million women diagnosed with breast cancer and 670,000 deaths worldwide. Breast cancer occurs in every country in the world in women of any age after puberty, but with increasing rates in later life. The song that closes the brand new album 'Rise of the Underdog' is dedicated to all women who have this problem and also calls on all ladies to get checked in time and thus prevent the further progression of this nasty disease. Garyball Corpse in #worldmusicday2024 is participating with brand new album 'Rise of the Underdog' @ https://lnkd.in/dE-Axy2y #BramilArtExhibit #deathmetal #garyballcorpsegarybramil #metal #garybramil ©℗ 2024. Bramil Art Exhibit

Join us for “Immunotherapy Frontiers: Cellular Therapies and Biomarker Discordance in Solid Tumors,” a transformative webinar sponsored by GenomeWeb and Precision Medicine Online. ✨ This is the 1st installment of a two-part MTB Spring series: https://lnkd.in/e3s2KmjW 🗓️: Tuesday, May 7th 🕐: 1-2 pm EST 💻 REGISTER HERE: https://lnkd.in/eXhu3wup The approval of tumor-infiltrating lymphocytes (TILs) marks a significant advancement in cellular therapies for solid tumors, heralding a new chapter in immunotherapy. This presentation explores the nuanced decision-making process in immunotherapy selection, comparing the roles of microsatellite instability (MSI)/mismatch repair (MMR) status versus PD-L1 expression versus high tumor mutational burden (TMB), and addressing the challenges of discordant results between immunohistochemistry (IHC) for mismatch repair proteins and microsatellite instability testing. Through these insights, we aim to illuminate the path forward in harnessing immunotherapy's full potential for solid tumors. Clarified Precision Medicine Todd Knepper Noor Naffakh Mark Zangardi Beth Gustafson

⭐ It's a good day for hope, bad day for cancer! The latest report from American Association for Cancer Research revealed that the age-adjusted overall cancer death rate in the U.S. fell by 33% between 1991 and 2020. The report also highlighted cancer immunotherapy’s emerging role as a game-changing treatment modality. 👏 We are proud to have funded clinical trials for patients that helped contribute to four FDA approved life-saving immunotherapy cancer treatments: Yervoy, Opdivo, Tecentriq and Keytruda. Help us give cancer more bad days. Donate at swimacrossamerica.org. Read the full report: https://lnkd.in/eErwMtaj #swimacrossamerica #makingwavestofightcancer #poolswims #MakeWaves #openwaterswimming #WhyISwim #cancerresearch #immunotherapy #makeanimpact

1 in 2 person in the world will have cancer in their life time. That means 50% of you reading this post. Choose wisely your cancer treatment, as one of these treatment is just making profit of your life. Dustin Kunarri, at 2.5 year (1994) had very aggresive brain tumor, cured until now without conventional cancer therapy. Do you want cancer free? or toxic drug enters your body killing every cells? Choose wisely. https://lnkd.in/guewHSvu https://lnkd.in/gBkTzAAC. https://lnkd.in/gXGTUNX4

82 spots left to fill before March madness begins on Thursday! Please help us fill it for a good cause! I started this March Madness squares pool to help supplement our fundraising for the Leukemia & Lymphoma Society. If you're interested in joining, follow the link below (if it doesn't work, you can search for pool ID #547716). If you're new to Run Your Pool, you'll need to create a profile. This is run similarly to a Super Bowl pool in that each square will be assinged a winning score number and losing score number. Ex: Final score is 74-67, winning score number is 4, losing score umber is 7. Each square ($50) will then be your numbers for the entirety of the tournament and gets you a chance at winning in all 63 games. Payout will be as follows: First Round (32 games) = $25 Second Round (16 games) = $50 Sweet 16 (8 games) = $80 Elite 8 (4 games) = $125 Final Four (2 games) = $250 Championship = $500 Total payout = $3740. The balance will be donated to the Leukemia & Lymphoma Society. Numbers will be randomly generated after the squares are filled. I'm a little late getting this going, so apologies for that, but I think we can get it filled in time for the start of the tournament Thursday morning. Please share with anyone you think might be interested. Thank you! Payments can be sent to me via Venmo @Marc-Thompson-24. https://lnkd.in/gG4waX3Y

Anixa CEO Dr. Amit Kumar dives into the recent positive data from the Phase 1 breast cancer vaccine trial. If you missed the news, watch the update here: https://bit.ly/3T9Gbsk #BreastCancerAwareness #Oncology #OncNews #Biotech #Biosciences

New YouTube video on Aethlon Medical where I explain our upcoming clinical trial involving the Hemopurifier to remove EVs from the circulation that may be involved in resistance to anti-PD-1 antibodies #AethlonMedical #Oncology #exosomes #EVs #PDL1 #Opdivo #Keytruda

So I'm heading out tomorrow to do something hard. If it goes well it'll be hard to do, if it goes badly it'll be hard to take, so either way, it's something hard. Every hour on the hour from 12.00 tomorrow foe as long as I can, I'll run a 6.7km lap of a forest trail. In comparison to marathons or shorter, that's quite slow, but against the standard of ultramarathons it's a breakneck pace that would win you some big races if you could keep it up. It's a forgiving format at the start, then hour by hour it's less and less so, because you have to toe that line to answer the gun whether you're ready or not. You can make yourself a little time to rest, but if you go fast enough to make a longer break, you're going too fast to benefit from it and you'll have thrown away your race a few laps before it becomes obvious. Like Sisyphus, I'll just have to keep pushing up that hill and embrace the task. It's challenge no. 2 in Project '24 for Diabetes Ireland and the Irish Cancer Society. If you click the link below you can find out why I'm doing it and how you can help. We'll post some updates on this https://lnkd.in/gDm3fe8X tomorrow. If you want to follow along, some marks to judge my progress by; 7 laps - 46.9km, a few km more than a marathon and the minimum I'd be OK with if I absolutely had to stop. 8 laps - 53.6km. 50km is often said to be the the shortest ultramarathon, so it's a target. 10 laps - 67km, a few km more than 1.5 marathons 12 laps, 80.4km, my longest run by a measly 400m so I'll have to do at least one more to feel I've genuinely gone further than ever. 14 laps, 93.8km, over two marathons. I'd be happy with that, but being so close to the ton, I'd hope to have one more in me for... 15 laps, 100.5km. Ambitious, but doable if none of my injuries seize up. After that, the maths is obvious, but the rest is guesswork and anything could happen. Hopefully it'll be something good. https://lnkd.in/ejbThG4r